北京市嘉源律师事务所 关于科兴生物制药股份有限公司 差异化分红事项的法律意见书 号所 LAW OFFICE 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 . 二〇二五年五月 EUM = S PT YUAN LAW OFFICE 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI `AN 致:科兴生物制药股份有限公司 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 差异化分红事项的法律意见书 嘉源(2025)-03-040 敬启者: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证 券法》(以下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第7号— 一回购股份》(以下简称"《回购股份指引》")等法律、法规和规范性文件以及《科 兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规定,北京市嘉 源律师事务所(以下简称"本所")接受科兴生物制药股份有限公司(以下简称"科 兴制药"或"公司"）的委托,就公司本次差异化分红事项出具本法律意见书。 为出具本法 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-033 科兴生物制药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/11 | 2025/6/12 | 2025/6/12 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经科兴生物制药股份有限公司（以下简称"公司"）2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件以及《公司章程》的有关规定，公司回 ...

中国经济网北京6月5日讯科兴制药(688136.SH)昨晚发布股东减持股份计划公告。截至公告披露日，深 圳科益医药控股有限公司(以下简称"科益医药")直接持有科兴制药131,778,347股，占公司总股本的比例 为66.01%。科益医药直接持有的股份为其在公司首次公开发行前取得的股份，上述股份均已上市流 通。 科兴制药2020年以来3次分红合计派发现金红利5158.71万元。 科益医药本次拟通过集中竞价或大宗交易方式减持所持有的公司股份为不超过5,989,200股，即不超过公 司目前股份总数的3.00%。本次减持计划自公告披露之日起15个交易日后的3个月内(根据中国证券监督 管理委员会及上海证券交易所规定禁止减持的期间除外)进行。若减持计划实施期间公司发生送股、资 本公积金转增股本、配股等股份变动事项，将对拟减持股份数量和比例进行相应调整。 科兴制药2024年年度报告显示，深圳科益医药控股有限公司为公司控股股东，邓学勤为公司实际控制 人。 公司第二届董事会第二十二次会议审议通过《关于公司2024年度利润分配方案的议案》，公司2024年度 利润分配预案为：拟以实施权益分派股权登记日的总股本为基数，向全体股东按每 ...

Core Viewpoint - The collaboration between Kexing Pharmaceutical and Dongyao Pharmaceutical has led to the approval of a biosimilar product, Bevacizumab injection, by the Nigerian Food and Drug Administration, marking a significant advancement in the company's strategy in the African pharmaceutical market [1] Group 1 - The approved Bevacizumab injection is indicated for the treatment of metastatic colorectal cancer, advanced or metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer [1] - The approval signifies an important step for the company in establishing its presence in the core pharmaceutical market of Africa [1]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

1、工信部部署推动 人工智能产业发展和赋能新型工业化，统筹布局通用大模型和行业专用大模型，注 重软硬件适配，加快建立高质量行业数据集，提升重点产品装备的智能化水平。2、香港证监会正考虑 为专业投资者引入虚拟 资产衍生品交易，鼓励本地和国际企业探索虚拟资产技术的创新及应用。3、国 家能源局组织开展新型电力系统建设第一批试点工作，统筹地区存量及增量数据中心绿电需求和新能源 资源条件，协同规划布局算力与电力项目。4、财政部、住房城乡建设部组织开展了2025年度中央财政 支持实施城市更新行动评选，拟支持北京、天津等20城实施城市更新行动。5、 金山办公：继续聘任雷 军为公司名誉董事长。 科兴制药：控股股东科益医药拟减持不超3%公司股份。3连板 中衡设计：公 司"低空经济"、"商业航天"相关项目设计收入占比较小。7天5板 乐惠国际：公司鲜啤业务占比较小 尚 处于亏损阶段。5天4板 合兴股份：部分董监高人员在本次股票交易异常波动期间根据减持计划减持15.3 万股公司股票。 万泰生物：公司九价HPV疫苗上市许可申请获得批准。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-032 科兴生物制药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，深圳科益医药控股有限公司（以下简称"科益医药"） 直接持有科兴生物制药股份有限公司（以下简称"公司"）131,778,347 股，占 公司总股本的比例为 66.01%。科益医药直接持有的股份为其在公司首次公开发 行前取得的股份，上述股份均已上市流通。 减持计划的主要内容 科益医药本次拟通过集中竞价或大宗交易方式减持所持有的公司股份为不 超过 5,989,200 股，即不超过公司目前股份总数的 3.00%。本次减持计划自公告 披露之日起 15 个交易日后的 3 个月内（根据中国证券监督管理委员会及上海证 券交易所规定禁止减持的期间除外）进行。若减持计划实施期间公司发生送股、 资本公积金转增股本、配股等股份变动事项，将对拟减持股份数量和比例进行相 应调整。 | 股东名称 | 深圳科益医药控股有限 ...

科兴制药：股东科益医药拟通过集中竞价或大宗交易方式减持不超过598.92万股，即不超过公司目前股 份总数的3.00%。 ...

重要新闻 1. 国务院：政府部门应当科学合理确定政务数据共享属性，不得通过擅自增设条件等方式阻碍、影响政 务数据共享 李强签署国务院令，公布《政务数据共享条例》。条例提到，政府部门应当科学合理确定政务数据共享 属性，不得通过擅自增设条件等方式阻碍、影响政务数据共享。对属于有条件共享类的政务数据，政府 部门应当在政务数据目录中列明共享范围、使用用途等共享使用条件。对属于不予共享类的政务数据， 政府部门应当在政务数据目录中列明理由，并明确相应的法律、行政法规以及国务院决定依据。（新华 社） 2. 商务部等五部门组织开展2025年新能源汽车下乡活动，特斯拉Model 3、Model Y车型在列 工业和信息化部、国家发展改革委、农业农村部、商务部、国家能源局组织开展2025年新能源汽车下乡 活动。选取一批新能源汽车推广比例不高、市场潜力较大的典型县域城市，举行若干场专场活动；以此 为中心辐射周边乡镇，结合地区特点开展若干场特色活动。与县域充换电设施补短板试点、智能网联汽 车"车路云一体化"试点等工作形成协同效应，推动优质资源向乡村地区倾斜。其中，特斯拉Model 3、 Model Y车型在列。 3. 商务部：希望欧方 ...

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding recent developments and their potential impacts on company performance. Company Announcements - Shuyou Shen's application for conditional listing of STSP-0601 has been accepted by the National Medical Products Administration, aimed at treating bleeding in adult patients with hemophilia A or B, but its impact on current performance is uncertain [3] - Debang Co. has clarified that it has not yet applied autonomous driving logistics vehicles, and this concept will not affect its performance [4] - Hu Xianfu has been elected as the chairman of China Shipbuilding, with a term until the board's term ends [7] - Baili Electric reported that its involvement in controlled nuclear fusion projects has minimal revenue impact, accounting for less than 1% of total revenue in 2024 [8] - Wanrun Co.'s chairman Huang Yiwu has resigned due to work adjustments, and he will not hold any positions in the company post-resignation [9] - Kexing Pharmaceutical announced that its innovative drug projects are still in the preclinical stage, highlighting the high risks and uncertainties involved in drug development [10] Performance Metrics - Sairisi reported that the cumulative sales of the Wanjie M9 reached 50,500 units from January to May, a year-on-year increase of 19.46% [11] - Guangzhou Port expects a 4.3% year-on-year increase in container throughput for May, with a total of 2.309 million TEUs [12] Shareholding Changes - Guokang Biochemical announced that major shareholders plan to reduce their holdings by up to 6% of the company's shares [13] - Far East Co. plans to reduce its holdings by up to 2.30% due to funding needs [14] Share Buybacks - Goodway plans to repurchase shares worth between 100 million and 150 million yuan, with a maximum price of 53 yuan per share [15] - Industrial Fulian has repurchased 7,697,400 shares, using a total of approximately 147 million yuan [16][17] Strategic Partnerships - Siwei Tuxin signed a strategic cooperation framework agreement with Alibaba Cloud to enhance its automotive intelligence strategy over the next five years [18] - Del Co. plans to invest approximately 300 million yuan in new lithium battery pilot and industrialization projects [19]